NZ714625A - Kinase inhibitors for the treatment of cancer - Google Patents
Kinase inhibitors for the treatment of cancerInfo
- Publication number
- NZ714625A NZ714625A NZ714625A NZ71462513A NZ714625A NZ 714625 A NZ714625 A NZ 714625A NZ 714625 A NZ714625 A NZ 714625A NZ 71462513 A NZ71462513 A NZ 71462513A NZ 714625 A NZ714625 A NZ 714625A
- Authority
- NZ
- New Zealand
- Prior art keywords
- aad
- cancer
- treatment
- kinase inhibitors
- mesothelioma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed are aminoacetonitrile derivatives AAD 450, AAD 907, AAD 970, AAD 1154, AAD 004, AAD 2009, AAD 1336 and AAD 1470 (as shown in drawing) that are useful in the treatment of cancer through kinase inhibition. Cancers include ovarian cancer, breast cancer, prostate cancer and mesothelioma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012901199A AU2012901199A0 (en) | 2012-03-23 | Kinase inhibitors for the Treatment of Cancer | |
NZ630807A NZ630807A (en) | 2012-03-23 | 2013-03-22 | Kinase inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ714625A true NZ714625A (en) | 2017-02-24 |
Family
ID=49221707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ714625A NZ714625A (en) | 2012-03-23 | 2013-03-22 | Kinase inhibitors for the treatment of cancer |
NZ630807A NZ630807A (en) | 2012-03-23 | 2013-03-22 | Kinase inhibitors for the treatment of cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ630807A NZ630807A (en) | 2012-03-23 | 2013-03-22 | Kinase inhibitors for the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (2) | US9308193B2 (en) |
EP (2) | EP3061451B1 (en) |
JP (2) | JP6165231B2 (en) |
KR (1) | KR102055176B1 (en) |
CN (2) | CN105534969B (en) |
AU (2) | AU2013234869B2 (en) |
CA (1) | CA2868120C (en) |
ES (2) | ES2732229T3 (en) |
HK (2) | HK1223832A1 (en) |
NZ (2) | NZ714625A (en) |
PL (1) | PL2817286T3 (en) |
WO (1) | WO2013138863A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014022879A1 (en) | 2012-08-06 | 2014-02-13 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
ES2940890T3 (en) * | 2013-11-01 | 2023-05-12 | Pitney Pharmaceuticals Pty Ltd | Pharmaceutical combinations for the treatment of cancer |
JPWO2021177334A1 (en) * | 2020-03-04 | 2021-09-10 | ||
EP4149454A1 (en) * | 2020-05-11 | 2023-03-22 | Pitney Pharmaceuticals Pty Limited | Use of aminoacetonitrile compounds for the treatment of infection and disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584305A (en) * | 1972-08-17 | 1986-04-22 | Janssen Pharmaceutica N.V. | Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole |
JPH0832638B2 (en) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | Adjuvant formulation comprising submicron oil droplet emulsion |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AT408615B (en) | 1998-09-15 | 2002-01-25 | Immuno Ag | NEW INFLUENCE VIRUS VACCINE COMPOSITION |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
AR036054A1 (en) * | 2001-06-15 | 2004-08-04 | Novartis Ag | USE OF AMINOACETONITRILE COMPOUNDS FOR THE CONTROL OF PESTS, A COMPOSITION AND A PROCESS FOR SUCH CONTROL AND A PHARMACEUTICAL COMPOSITION AGAINST PARASITES |
GB0402677D0 (en) * | 2003-11-06 | 2004-03-10 | Novartis Ag | Organic compounds |
AR049391A1 (en) * | 2004-06-10 | 2006-07-26 | Novartis Ag | DERIVATIVES OF AMINOACETONITRILE AND ITS USE TO CONTROL PARASITES IN HOT BLOOD ANIMALS |
AR054822A1 (en) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | ADMISSION IMMUNE EMULSION |
CN102127074A (en) * | 2010-12-17 | 2011-07-20 | 中国药科大学 | 6-sulfamyl substituted-beta-carboline-1-ketone cell cycle protein dependent kinase 2 inhibitor and application thereof |
-
2013
- 2013-03-22 WO PCT/AU2013/000290 patent/WO2013138863A1/en active Application Filing
- 2013-03-22 NZ NZ714625A patent/NZ714625A/en not_active IP Right Cessation
- 2013-03-22 PL PL13764613T patent/PL2817286T3/en unknown
- 2013-03-22 CA CA2868120A patent/CA2868120C/en active Active
- 2013-03-22 AU AU2013234869A patent/AU2013234869B2/en active Active
- 2013-03-22 CN CN201610041111.6A patent/CN105534969B/en not_active Expired - Fee Related
- 2013-03-22 JP JP2015500717A patent/JP6165231B2/en active Active
- 2013-03-22 ES ES16162192T patent/ES2732229T3/en active Active
- 2013-03-22 EP EP16162192.5A patent/EP3061451B1/en active Active
- 2013-03-22 CN CN201380024851.3A patent/CN104364232B/en active Active
- 2013-03-22 US US14/387,270 patent/US9308193B2/en active Active
- 2013-03-22 NZ NZ630807A patent/NZ630807A/en unknown
- 2013-03-22 EP EP13764613.9A patent/EP2817286B1/en active Active
- 2013-03-22 KR KR1020147029526A patent/KR102055176B1/en active IP Right Grant
- 2013-03-22 ES ES13764613.9T patent/ES2685612T3/en active Active
-
2015
- 2015-06-19 HK HK16112097.9A patent/HK1223832A1/en unknown
- 2015-06-19 HK HK15105896.7A patent/HK1205500A1/en unknown
-
2016
- 2016-03-01 US US15/057,628 patent/US20160220527A1/en not_active Abandoned
- 2016-06-27 AU AU2016204389A patent/AU2016204389B2/en not_active Ceased
-
2017
- 2017-02-28 JP JP2017036116A patent/JP6483736B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2013234869A1 (en) | 2014-10-02 |
JP6483736B2 (en) | 2019-03-13 |
EP3061451A1 (en) | 2016-08-31 |
US9308193B2 (en) | 2016-04-12 |
CN104364232A (en) | 2015-02-18 |
PL2817286T3 (en) | 2018-11-30 |
JP6165231B2 (en) | 2017-07-19 |
ES2732229T3 (en) | 2019-11-21 |
KR102055176B1 (en) | 2019-12-12 |
CN105534969A (en) | 2016-05-04 |
KR20140145604A (en) | 2014-12-23 |
JP2017125041A (en) | 2017-07-20 |
AU2016204389B2 (en) | 2018-01-25 |
HK1223832A1 (en) | 2017-08-11 |
US20150051290A1 (en) | 2015-02-19 |
US20160220527A1 (en) | 2016-08-04 |
HK1205500A1 (en) | 2015-12-18 |
CN104364232B (en) | 2017-05-31 |
JP2015510898A (en) | 2015-04-13 |
WO2013138863A1 (en) | 2013-09-26 |
ES2685612T3 (en) | 2018-10-10 |
AU2013234869B2 (en) | 2016-06-30 |
EP2817286A4 (en) | 2015-09-02 |
AU2016204389A1 (en) | 2016-07-14 |
EP2817286A1 (en) | 2014-12-31 |
CA2868120C (en) | 2019-02-19 |
NZ630807A (en) | 2016-04-29 |
EP2817286B1 (en) | 2018-06-06 |
EP3061451B1 (en) | 2019-05-08 |
CN105534969B (en) | 2019-04-05 |
CA2868120A1 (en) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291000A (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
PH12015502091A1 (en) | Cdc7 inhibitors | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
MX2015007205A (en) | Histone demethylase inhibitors. | |
PL2922828T3 (en) | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer | |
NZ731797A (en) | Dna-pk inhibitors | |
EP2925744A4 (en) | Pyrimidine-2,4-diamine derivatives for treatment of cancer | |
MX2019010098A (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer. | |
MX2016001136A (en) | Oxoquinazolinyl-butanamide derivatives. | |
MX2016008042A (en) | Imidazopyrazinone derivatives. | |
MX2015013021A (en) | 5-bromo-indirubins. | |
PH12015502757A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
NZ714625A (en) | Kinase inhibitors for the treatment of cancer | |
WO2012166463A3 (en) | Aminooxazole inhibitors of cyclin dependent kinases | |
HK1215535A1 (en) | Cabazitaxel and its use for treating metastatic prostate cancers | |
MX2015014036A (en) | Inhibitors of metastasis. | |
PH12015502756A1 (en) | Combination of imidazopyridazine derivative and a mitotic agent for the treatment of cancer | |
EP3052116A4 (en) | Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency | |
EP3079771A4 (en) | Sgk1 inhibitors for treatment of prostate cancer | |
MY182434A (en) | Certain chemical entities, compositions, and methods | |
IN2013DE02958A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2020 BY SPRUSON + FERGUSON Effective date: 20170630 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY CPA GLOBAL Effective date: 20200206 |
|
LAPS | Patent lapsed |